Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Crinetics Pharmaceuticals, Inc. (CRNX) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Crinetics Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1658247.
Total stock buying since 2018: $62,557,846.
Total stock sales since 2018: $87,997,212.
Total stock option exercises since 2018: $11,949,871.
Insider Buying | Insider Sales | Option Exercises | ||||
---|---|---|---|---|---|---|
Year | Shares | Value | Shares | Value | Shares | Value |
2025 | 0 | $0 | 191,760 | $6,512,495 | 226,940 | $1,626,586 |
2024 | 0 | $0 | 545,466 | $25,962,362 | 515,032 | $7,539,194 |
2023 | 5,000 | $110,300 | 383,179 | $10,181,084 | 306,583 | $2,494,925 |
2022 | 157,515 | $3,499,983 | 302,298 | $7,188,873 | 23,500 | $109,933 |
2021 | 1,504,136 | $28,759,995 | 107,714 | $2,698,465 | 136,383 | $134,958 |
2020 | 1,076,428 | $15,064,992 | 726,081 | $11,057,337 | 25,329 | $18,490 |
2019 | 0 | $0 | 1,087,492 | $24,396,596 | 13,500 | $25,785 |
2018 | 870,180 | $15,122,576 | 0 | $0 | 0 | $0 |
Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
---|---|---|---|---|---|---|
year-month | Shares | Value | Shares | Value | Shares | Value |
2025-09 | 0 | $0 | 5,000 | $160,500 | 5,000 | $84,450 |
2025-08 | 0 | $0 | 36,492 | $1,102,336 | 30,000 | $506,700 |
2025-06 | 0 | $0 | 97,483 | $3,141,877 | 88,170 | $493,311 |
2025-04 | 0 | $0 | 0 | $0 | 81,270 | $155,225 |
2025-03 | 0 | $0 | 32,785 | $1,131,082 | 0 | $0 |
2025-02 | 0 | $0 | 5,000 | $195,350 | 5,000 | $84,450 |
2025-01 | 0 | $0 | 15,000 | $781,350 | 17,500 | $302,450 |
2024-12 | 0 | $0 | 10,000 | $575,700 | 0 | $0 |
2024-11 | 0 | $0 | 501 | $28,316 | 0 | $0 |
2024-10 | 0 | $0 | 14,375 | $785,306 | 14,375 | $242,793 |
2024-09 | 0 | $0 | 26,035 | $1,331,052 | 25,000 | $382,250 |
2024-08 | 0 | $0 | 6,000 | $302,610 | 0 | $0 |
2024-07 | 0 | $0 | 103,431 | $5,353,233 | 99,504 | $1,769,168 |
2024-06 | 0 | $0 | 54,085 | $2,381,162 | 47,129 | $594,107 |
2024-05 | 0 | $0 | 113,448 | $5,598,691 | 107,448 | $997,117 |
2024-04 | 0 | $0 | 55,326 | $2,652,816 | 75,326 | $661,018 |
2024-03 | 0 | $0 | 131,890 | $5,870,921 | 121,875 | $2,557,148 |
2024-01 | 0 | $0 | 30,375 | $1,082,555 | 24,375 | $335,593 |
2023-12 | 0 | $0 | 12,583 | $438,954 | 9,583 | $161,856 |
2023-11 | 0 | $0 | 213,000 | $6,494,459 | 260,000 | $2,044,299 |
2023-10 | 0 | $0 | 7,000 | $210,000 | 7,000 | $84,070 |
2023-08 | 0 | $0 | 0 | $0 | 10,000 | $19,100 |
2023-07 | 0 | $0 | 50,000 | $1,010,315 | 0 | $0 |
2023-06 | 5,000 | $110,300 | 80,922 | $1,657,856 | 20,000 | $185,600 |
Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-09-02 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 5,000 | 32.10 | 160,500 |
2025-09-02 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 5,000 | 16.89 | 84,450 |
2025-08-22 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 30,000 | 30.43 | 912,900 |
2025-08-22 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 30,000 | 16.89 | 506,700 |
2025-08-20 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 6,492 | 29.18 | 189,436 |
2025-06-12 | Betz Stephen F. (Chief Scientific Officer) | Sale | 97,483 | 32.23 | 3,141,877 |
2025-06-12 | Betz Stephen F. (Chief Scientific Officer) | Option Ex | 88,170 | 5.59 | 493,311 |
2025-04-02 | Struthers Richard Scott (President & CEO) | Option Ex | 81,270 | 1.91 | 155,225 |
2025-03-19 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 2,515 | 34.50 | 86,767 |
2025-03-19 | Betz Stephen F. (Chief Scientific Officer) | Sale | 5,770 | 34.50 | 199,065 |
2025-03-19 | Knight Jeff E. (Chief Operating Officer) | Sale | 7,162 | 34.50 | 247,089 |
2025-03-19 | Struthers Richard Scott (President & CEO) | Sale | 17,338 | 34.50 | 598,161 |
2025-02-03 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 5,000 | 39.07 | 195,350 |
2025-02-03 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 5,000 | 16.89 | 84,450 |
2025-01-07 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 2,500 | 19.64 | 49,100 |
2025-01-03 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 15,000 | 52.09 | 781,350 |
2025-01-03 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 15,000 | 16.89 | 253,350 |
2024-12-02 | Struthers Richard Scott (President & CEO) | Sale | 10,000 | 57.57 | 575,700 |
2024-11-22 | Knight Jeff E. (Chief Operating Officer) | Sale | 501 | 56.52 | 28,316 |
2024-10-03 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 14,375 | 54.63 | 785,306 |
2024-10-03 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 14,375 | 16.89 | 242,793 |
2024-09-26 | Wilson Marc (CFO) | Sale | 25,000 | 51.11 | 1,277,750 |
2024-09-26 | Wilson Marc (CFO) | Option Ex | 25,000 | 15.29 | 382,250 |
2024-09-10 | Betz Stephen F. (Chief Scientific Officer) | Sale | 1,035 | 51.50 | 53,302 |
2024-08-26 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 53.19 | 159,570 |
2024-08-12 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 47.68 | 143,040 |
2024-07-25 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 53.43 | 160,290 |
2024-07-25 | Wilson Marc (CFO) | Sale | 19,056 | 53.88 | 1,026,737 |
2024-07-25 | Wilson Marc (CFO) | Option Ex | 19,056 | 9.28 | 176,839 |
2024-07-15 | Knight Jeff E. (Chief Operating Officer) | Sale | 27,000 | 55.00 | 1,485,000 |
2024-07-15 | Knight Jeff E. (Chief Operating Officer) | Option Ex | 26,073 | 21.21 | 553,086 |
2024-07-15 | Wilson Marc (CFO) | Sale | 25,000 | 55.00 | 1,375,000 |
2024-07-15 | Wilson Marc (CFO) | Option Ex | 25,000 | 20.02 | 500,500 |
2024-07-05 | Hassard James (Chief Commercial Officer) | Sale | 15,000 | 44.08 | 661,200 |
2024-07-05 | Hassard James (Chief Commercial Officer) | Option Ex | 15,000 | 19.73 | 295,950 |
2024-07-03 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 14,375 | 44.87 | 645,006 |
2024-07-03 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 14,375 | 16.89 | 242,793 |
2024-06-28 | Wilson Marc (CFO) | Sale | 32,129 | 43.61 | 1,401,145 |
2024-06-28 | Wilson Marc (CFO) | Option Ex | 32,129 | 9.28 | 298,157 |
2024-06-26 | Knight Jeff E. (Chief Operating Officer) | Sale | 956 | 44.38 | 42,427 |
2024-06-25 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 45.37 | 136,110 |
2024-06-21 | Hassard James (Chief Commercial Officer) | Sale | 15,000 | 44.66 | 669,900 |
2024-06-21 | Hassard James (Chief Commercial Officer) | Option Ex | 15,000 | 19.73 | 295,950 |
2024-06-10 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 43.86 | 131,580 |
2024-05-28 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 47.49 | 142,470 |
2024-05-10 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 49.43 | 148,290 |
2024-05-08 | Struthers Richard Scott (President & CEO) | Sale | 107,448 | 49.40 | 5,307,931 |
2024-05-08 | Struthers Richard Scott (President & CEO) | Option Ex | 107,448 | 9.28 | 997,117 |
2024-04-15 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 14,375 | 44.47 | 639,256 |
2024-04-15 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 14,375 | 16.89 | 242,793 |
2024-04-15 | Struthers Richard Scott (President & CEO) | Option Ex | 20,000 | 1.91 | 38,200 |
2024-04-04 | Struthers Richard Scott (President & CEO) | Sale | 40,951 | 49.17 | 2,013,560 |
2024-04-04 | Struthers Richard Scott (President & CEO) | Option Ex | 40,951 | 9.28 | 380,025 |
2024-03-28 | Okey Stephanie (Director) | Sale | 17,500 | 46.38 | 811,650 |
2024-03-28 | Okey Stephanie (Director) | Option Ex | 17,500 | 18.29 | 320,075 |
2024-03-22 | Knight Jeff E. (Chief Operating Officer) | Sale | 32,359 | 44.80 | 1,449,844 |
2024-03-22 | Knight Jeff E. (Chief Operating Officer) | Option Ex | 30,000 | 23.98 | 719,400 |
2024-03-20 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 15,089 | 44.29 | 668,246 |
2024-03-20 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 14,375 | 16.89 | 242,793 |
2024-03-20 | Fust Matthew K (Director) | Sale | 60,000 | 44.05 | 2,643,300 |
2024-03-20 | Fust Matthew K (Director) | Option Ex | 60,000 | 21.25 | 1,274,880 |
2024-03-19 | Wilson Marc (CFO) | Sale | 6,942 | 42.91 | 297,881 |
2024-01-25 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 37.26 | 111,780 |
2024-01-10 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 37.65 | 112,950 |
2024-01-03 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 14,375 | 35.00 | 503,125 |
2024-01-03 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 14,375 | 16.89 | 242,793 |
2024-01-02 | Wilson Marc (CFO) | Sale | 10,000 | 35.47 | 354,700 |
2024-01-02 | Wilson Marc (CFO) | Option Ex | 10,000 | 9.28 | 92,800 |
2023-12-26 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 35.89 | 107,670 |
2023-12-21 | Pizzuti Dana (Chief Med and Dev Officer) | Sale | 9,583 | 34.57 | 331,284 |
2023-12-21 | Pizzuti Dana (Chief Med and Dev Officer) | Option Ex | 9,583 | 16.89 | 161,856 |
2023-11-27 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 31.84 | 95,520 |
2023-11-09 | Struthers Richard Scott (President & CEO) | Option Ex | 50,000 | 1.91 | 95,500 |
2023-11-03 | Struthers Richard Scott (President & CEO) | Sale | 199,082 | 30.56 | 6,083,945 |
2023-11-03 | Struthers Richard Scott (President & CEO) | Option Ex | 199,082 | 9.28 | 1,847,480 |
2023-11-02 | Struthers Richard Scott (President & CEO) | Sale | 918 | 29.95 | 27,494 |
2023-11-02 | Struthers Richard Scott (President & CEO) | Option Ex | 918 | 9.28 | 8,519 |
2023-11-01 | Wilson Marc (CFO) | Sale | 10,000 | 28.75 | 287,500 |
2023-11-01 | Wilson Marc (CFO) | Option Ex | 10,000 | 9.28 | 92,800 |
2023-10-17 | Krasner Alan Seth (Chief Medical Officer) | Sale | 7,000 | 30.00 | 210,000 |
2023-10-17 | Krasner Alan Seth (Chief Medical Officer) | Option Ex | 7,000 | 12.01 | 84,070 |
2023-08-14 | Struthers Richard Scott (President & CEO) | Option Ex | 10,000 | 1.91 | 19,100 |
2023-07-13 | Struthers Richard Scott (President & CEO) | Sale | 14,157 | 20.35 | 288,094 |
2023-07-12 | Struthers Richard Scott (President & CEO) | Sale | 11,459 | 20.17 | 231,128 |
2023-07-11 | Struthers Richard Scott (President & CEO) | Sale | 24,384 | 20.14 | 491,093 |
2023-06-20 | Wilson Marc (CFO) | Sale | 30,922 | 19.96 | 617,357 |
2023-06-20 | Wilson Marc (CFO) | Option Ex | 20,000 | 9.28 | 185,600 |
2023-06-16 | Struthers Richard Scott (President & CEO) | Sale | 50,000 | 20.81 | 1,040,499 |
2023-06-08 | Vivaldi Coelho Rogerio (Director) | Buy | 5,000 | 22.06 | 110,300 |
2023-04-05 | Pizzuti Dana (Chief Development Officer) | Sale | 8,212 | 16.15 | 132,623 |
2023-02-01 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,126 | 19.59 | 61,238 |
2023-01-25 | Betz Stephen F. (Chief Scientific Officer) | Sale | 8,336 | 21.07 | 175,639 |
2022-12-01 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,126 | 17.84 | 55,767 |
2022-11-15 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,126 | 18.72 | 58,518 |
2022-10-17 | Betz Stephen F. (Chief Scientific Officer) | Sale | 6,252 | 17.73 | 110,846 |
2022-10-12 | Struthers Richard Scott (President & CEO) | Option Ex | 11,100 | 1.91 | 21,201 |
2022-10-03 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,126 | 19.64 | 61,394 |
2022-09-15 | Betz Stephen F. (Chief Scientific Officer) | Sale | 20,840 | 21.01 | 437,845 |
2022-07-26 | Knight Jeff E. (Chief Operating Officer) | Sale | 1,152 | 20.70 | 23,846 |
2022-07-13 | Fust Matthew K (Director) | Sale | 5,700 | 20.96 | 119,454 |
2022-07-13 | Fust Matthew K (Director) | Option Ex | 5,700 | 1.45 | 8,265 |
2022-05-02 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,247 | 20.10 | 65,251 |
2022-04-18 | Betz Stephen F. (Chief Scientific Officer) | Sale | 5,664 | 25.81 | 146,187 |
2022-04-18 | Edelman Joseph (10% Owner) | Buy | 157,515 | 22.22 | 3,499,983 |
2022-04-13 | Struthers Richard Scott (President & CEO) | Sale | 138,643 | 26.49 | 3,672,930 |
2022-04-05 | Struthers Richard Scott (President & CEO) | Sale | 21,357 | 25.34 | 541,229 |
2022-04-04 | Betz Stephen F. (Chief Scientific Officer) | Sale | 9,000 | 23.97 | 215,766 |
2022-04-01 | Betz Stephen F. (Chief Scientific Officer) | Sale | 4,164 | 21.80 | 90,775 |
2022-03-31 | Betz Stephen F. (Chief Scientific Officer) | Sale | 4,164 | 21.06 | 87,698 |
2022-03-15 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,123 | 18.94 | 59,149 |
2022-03-01 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,123 | 19.73 | 61,616 |
2022-03-01 | Madan Ajay (Chief Development Officer) | Sale | 9,000 | 19.88 | 178,920 |
2022-02-15 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,123 | 18.64 | 58,212 |
2022-02-07 | Madan Ajay (Chief Development Officer) | Sale | 13,411 | 17.83 | 239,091 |
2022-02-01 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,123 | 18.79 | 58,681 |
2022-01-19 | Krasner Alan Seth (Chief Medical Officer) | Sale | 6,700 | 21.21 | 142,080 |
2022-01-19 | Krasner Alan Seth (Chief Medical Officer) | Option Ex | 6,700 | 12.01 | 80,467 |
2022-01-18 | Betz Stephen F. (Chief Scientific Officer) | Sale | 4,168 | 23.29 | 97,072 |
2022-01-03 | Betz Stephen F. (Chief Scientific Officer) | Sale | 7,168 | 28.02 | 200,847 |
2021-12-28 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 27.95 | 83,853 |
2021-12-15 | Betz Stephen F. (Chief Scientific Officer) | Sale | 5,668 | 24.14 | 136,825 |
2021-12-01 | Betz Stephen F. (Chief Scientific Officer) | Sale | 5,668 | 27.38 | 155,189 |
2021-11-16 | Betz Stephen F. (Chief Scientific Officer) | Sale | 1,500 | 27.97 | 41,955 |
2021-11-15 | Betz Stephen F. (Chief Scientific Officer) | Sale | 5,668 | 26.75 | 151,619 |
2021-11-08 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,900 | 28.42 | 110,845 |
2021-11-05 | Betz Stephen F. (Chief Scientific Officer) | Sale | 12,600 | 27.95 | 352,195 |
2021-11-01 | Betz Stephen F. (Chief Scientific Officer) | Sale | 5,668 | 24.79 | 140,509 |
2021-11-01 | Fust Matthew K (Director) | Sale | 8,954 | 25.50 | 228,327 |
2021-11-01 | Fust Matthew K (Director) | Option Ex | 8,954 | 1.91 | 17,102 |
2021-10-28 | Madan Ajay (Chief Development Officer) | Option Ex | 106,383 | .73 | 77,659 |
2021-10-27 | Betz Stephen F. (Chief Scientific Officer) | Sale | 3,000 | 24.00 | 71,991 |
2021-10-25 | Edelman Joseph (10% Owner) | Buy | 1,200,000 | 19.80 | 23,760,000 |
2021-10-21 | Betz Stephen F. (Chief Scientific Officer) | Sale | 1,042 | 21.10 | 21,984 |
2021-09-08 | Fust Matthew K (Director) | Sale | 6,046 | 25.50 | 154,173 |
2021-09-08 | Fust Matthew K (Director) | Option Ex | 6,046 | 1.91 | 11,547 |
2021-09-07 | Struthers Richard Scott (President & CEO) | Sale | 30,000 | 25.00 | 750,000 |
2021-07-26 | Fust Matthew K (Director) | Sale | 5,000 | 19.59 | 97,950 |
2021-07-26 | Fust Matthew K (Director) | Option Ex | 5,000 | 1.91 | 9,550 |
2021-07-19 | Fust Matthew K (Director) | Sale | 5,000 | 19.50 | 97,500 |
2021-07-19 | Fust Matthew K (Director) | Option Ex | 5,000 | 1.91 | 9,550 |
2021-07-12 | Fust Matthew K (Director) | Sale | 5,000 | 20.71 | 103,550 |
2021-07-12 | Fust Matthew K (Director) | Option Ex | 5,000 | 1.91 | 9,550 |
2021-04-08 | Edelman Joseph (10% Owner) | Buy | 304,136 | 16.44 | 4,999,995 |
2020-12-03 | Struthers Richard Scott (President & CEO) | Buy | 4,000 | 13.10 | 52,400 |
2020-12-02 | Struthers Richard Scott (President & CEO) | Buy | 1,000 | 12.60 | 12,600 |
2020-07-16 | Struthers Richard Scott (President & CEO) | Sale | 17,500 | 14.46 | 253,102 |
2020-07-15 | Struthers Richard Scott (President & CEO) | Sale | 17,500 | 15.30 | 267,715 |
2020-04-28 | Wierenga Wendall (Director) | Option Ex | 25,329 | .73 | 18,490 |
2020-04-17 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 84,598 | 15.40 | 1,302,809 |
2020-04-17 | Edelman Joseph (10% Owner) | Buy | 1,071,428 | 14.00 | 14,999,992 |
2020-04-16 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 30,190 | 15.20 | 458,888 |
2020-04-15 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 215,810 | 15.50 | 3,345,055 |
2020-04-07 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 6,115 | 14.20 | 86,833 |
2020-04-03 | Vivo Capital Surplus Fund Viii, L.p. | Sale | 300,000 | 13.80 | 4,140,000 |
2020-03-09 | Vivo Opportunity Fund, L.p. | Sale | 528 | 19.50 | 10,296 |
2020-02-10 | Vivo Opportunity Fund, L.p. | Sale | 7,555 | 21.40 | 161,677 |
2020-02-07 | Vivo Opportunity Fund, L.p. | Sale | 5,905 | 22.00 | 129,910 |
2020-02-04 | Vivo Opportunity Fund, L.p. | Sale | 13,460 | 22.80 | 306,888 |
2020-01-31 | Vivo Opportunity Fund, L.p. | Sale | 5,400 | 21.70 | 117,180 |
2020-01-30 | Vivo Opportunity Fund, L.p. | Sale | 7,600 | 22.10 | 167,960 |
2020-01-29 | Vivo Opportunity Fund, L.p. | Sale | 13,920 | 22.20 | 309,024 |
2019-12-16 | Fust Matthew K (Director) | Sale | 3,500 | 22.50 | 78,750 |
2019-12-16 | Fust Matthew K (Director) | Option Ex | 3,500 | 1.91 | 6,685 |
2019-08-05 | Struthers Richard Scott (President & CEO) | Option Ex | 10,000 | 1.91 | 19,100 |
2019-06-21 | Schwab Andrew J. (Other) | Sale | 250,000 | 22.20 | 5,550,000 |
2019-03-20 | Vivo Opportunity Fund, L.p. | Sale | 417,000 | 22.25 | 9,278,250 |
2019-03-18 | Schwab Andrew J. (10% Owner) | Sale | 154,839 | 24.25 | 3,755,000 |
2019-01-22 | Schwab Andrew J. (10% Owner) | Sale | 262,153 | 21.88 | 5,734,596 |
2018-07-20 | Vivo Opportunity Fund, L.p. | Buy | 353,180 | 17.93 | 6,333,576 |
2018-07-20 | Schwab Andrew J. (10% Owner) | Buy | 115,000 | 17.00 | 1,955,000 |
2018-07-20 | Krasner Alan Seth (Chief Medical Officer) | Buy | 2,000 | 17.00 | 34,000 |
2018-07-20 | Edelman Joseph (10% Owner) | Buy | 400,000 | 17.00 | 6,800,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of CRNX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Crinetics Pharmaceuticals, Inc. (symbol CRNX, CIK number 1658247) see the Securities and Exchange Commission (SEC) website.